Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.75 |
| ▸ | LTA4H | P09960 | 4/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28619862 | 0.87 | LTA4H (0.70) | MCHR1LTA4HHRH3SIGMAR1ALDH1A1 | |
| SCHEMBL4528896 | 0.85 | MCHR1 (1.00) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL12440195 | 0.84 | MCHR1 (0.59) | MCHR1LTA4HCHRM1HTR2AHRH3 | |
| SCHEMBL12441099 | 0.84 | MCHR1 (0.72) | MCHR1CHRM1HTR2AHRH3CYP2D6 | |
| SCHEMBL12441547 | 0.83 | MCHR1 (0.57) | MCHR1LTA4HCHRM1HTR2AHRH3 | |
| SCHEMBL12440372 | 0.82 | MCHR1 (0.74) | MCHR1LTA4HCHRM1HTR2AHRH3 | |
| SCHEMBL12440251 | 0.82 | MCHR1 (0.78) | MCHR1LTA4HCHRM1HTR2AHRH3 | |
| SCHEMBL14039753 | 0.82 | MCHR1 (0.78) | MCHR1LTA4HCHRM1HTR2AHRH3 | |
| SCHEMBL12440214 | 0.82 | MCHR1 (0.59) | MCHR1CHRM1HTR2AHRH3CYP2D6 | |
| SCHEMBL12440472 | 0.81 | MCHR1 (0.77) | MCHR1LTA4HCHRM1HTR2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558578-B1 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-03-13 | — | — | EP | disclosed |
| EP-2357173-A1 | New alkyne compounds with MCH-antagonistic activity and medicaments containing them | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | MCHR1 1/4885LTA4H 2076/4885CHRM1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.